Shohreh Varmeh

Shohreh Varmeh

Auto-generated profile, based on publicly available information

Shohreh Varmeh

Center for Precision Cancer Medicine, David H. Koch Institute for Integrative Cancer Research, Departments of Biology and Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2011 in Genes & Cancer
Verified
Journal Article
Open access
SVS. Varmeh
S. Varmeh
AEA. Egia
A. Egia
DMD. McGrouther
D. McGrouther
STS. R. Tahan
S. R. Tahan
ABArdeshir Bayat
Ardeshir Bayat
PPPier Paolo Pandolfi
Pier Paolo Pandolfi
Keloid scarring is a consequence of aberrant wound healing that leads to expansion of the scar beyond the confines of the skin injury. Keloid scars are characterized by excessive extracellular matrix disposition, prolonged proliferation of fibroblasts, increased angiogenesis, and inflammatory cell infiltration. There is no single satisfactory treatment for keloid, and it can lead to severe disfigurements and bodily dysfunction. Thus, clarification of the mechanisms underlying keloid formation, as well as those that prevent it from behaving as a malignant tumor, has significant consequences not only for treatment of keloid but also for the prevention of malignant tumor formation. Senescence is an irreversible form of growth arrest that has been shown to play a role, both in vitro and in vivo, in preventing malignant tumorigenesis upon oncogenic stress. In this study it is shown that fibroblasts embedded inside keloid scars proliferate at a slower rate compared with either those residing at the proliferative edges of the scar or normal fibroblasts. Likewise it is demonstrated that keloid fibroblasts exhibit a cell-cycle arrest with a G2/M DNA content and a higher rate of senescence. The results also indicate that levels of the tumor suppressor protein PML are higher in the active regions of keloid. The study therefore suggests that senescence is one possible mechanism by which keloid is maintained in a benign state. On this basis, "pro-senescence therapy" should be taken into consideration when designing treatment strategies for keloid.

21 November 2022 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JPJesse C. Patterson
Jesse C. Patterson
AVAndreas Varkaris
Andreas Varkaris
PCPeter J.P. Croucher
Peter J.P. Croucher
MRMaya Ridinger
Maya Ridinger
SDSusan Dalrymple
Susan Dalrymple
MYMichael B. Yaffe
Michael B. Yaffe
Abiraterone is a standard treatment for metastatic castrate-resistant prostate cancer (mCRPC) that slows disease progression by abrogating androgen synthesis and antagonizing the androgen receptor (AR). Here we report that inhibitors of the mitotic regulator polo-like kinase-1 (Plk1), including the clinically active third-generation Plk1 inhibitor onvansertib, synergizes with abiraterone in vitro and in vivo to kill a subset of cancer cells from a wide variety of tumor types in an androgen-independent manner. Gene-expression analysis identified an AR-independent synergy-specific gene set signature upregulated upon abiraterone treatment that is dominated by pathways related to mitosis and the mitotic spindle. Abiraterone treatment alone caused defects in mitotic spindle orientation, failure of complete chromosome condensation, and improper cell division independently of its effects on AR signaling. These effects, although mild following abiraterone monotherapy, resulted in profound sensitization to the antimitotic effects of Plk1 inhibition, leading to spindle assembly checkpoint-dependent mitotic cancer cell death and entosis. In a murine patient-derived xenograft model of abiraterone-resistant metastatic castration-resistant prostate cancer (mCRPC), combined onvansertib and abiraterone resulted in enhanced mitotic arrest and dramatic inhibition of tumor cell growth compared with either agent alone. Overall, this work establishes a mechanistic basis for the phase II clinical trial (NCT03414034) testing combined onvansertib and abiraterone in mCRPC patients and indicates this combination may have broad utility for cancer treatment. Significance: Abiraterone treatment induces mitotic defects that sensitize cancer cells to Plk1 inhibition, revealing an AR-independent mechanism for this synergistic combination that is applicable to a variety of cancer types.

9 December 2021 in Cancer Cell
Verified
Journal Article
Closed access
YKYoshinobu Konishi
Yoshinobu Konishi
RSRomanos Sklavenitis-Pistofidis
Romanos Sklavenitis-Pistofidis
HYHong Yue
Hong Yue
FFFederico Ferrari
Federico Ferrari
RRRobert A. Redd
Robert A. Redd
IGIrene M. Ghobrial
Irene M. Ghobrial

31 March 2023
Verified
Other
Open access
JPJesse C. Patterson
Jesse C. Patterson
AVAndreas Varkaris
Andreas Varkaris
PCPeter J.P. Croucher
Peter J.P. Croucher
MRMaya Ridinger
Maya Ridinger
SDSusan Dalrymple
Susan Dalrymple
MYMichael B. Yaffe
Michael B. Yaffe
Chromatin structure in abiraterone treated C4-2 cells

31 March 2023
Verified
Other
Open access
JPJesse C. Patterson
Jesse C. Patterson
AVAndreas Varkaris
Andreas Varkaris
PCPeter J.P. Croucher
Peter J.P. Croucher
MRMaya Ridinger
Maya Ridinger
SDSusan Dalrymple
Susan Dalrymple
MYMichael B. Yaffe
Michael B. Yaffe
Abiraterone is a standard treatment for metastatic castrate-resistant prostate cancer (mCRPC) that slows disease progression by abrogating androgen synthesis and antagonizing the androgen receptor (AR). Here we report that inhibitors of the mitotic regulator polo-like kinase-1 (Plk1), including the clinically active third-generation Plk1 inhibitor onvansertib, synergizes with abiraterone in vitro and in vivo to kill a subset of cancer cells from a wide variety of tumor types in an androgen-independent manner. Gene-expression analysis identified an AR-independent synergy-specific gene set signature upregulated upon abiraterone treatment that is dominated by pathways related to mitosis and the mitotic spindle. Abiraterone treatment alone caused defects in mitotic spindle orientation, failure of complete chromosome condensation, and improper cell division independently of its effects on AR signaling. These effects, although mild following abiraterone monotherapy, resulted in profound sensitization to the antimitotic effects of Plk1 inhibition, leading to spindle assembly checkpoint-dependent mitotic cancer cell death and entosis. In a murine patient-derived xenograft model of abiraterone-resistant metastatic castration-resistant prostate cancer (mCRPC), combined onvansertib and abiraterone resulted in enhanced mitotic arrest and dramatic inhibition of tumor cell growth compared with either agent alone. Overall, this work establishes a mechanistic basis for the phase II clinical trial (NCT03414034) testing combined onvansertib and abiraterone in mCRPC patients and indicates this combination may have broad utility for cancer treatment.Significance:Abiraterone treatment induces mitotic defects that sensitize cancer cells to Plk1 inhibition, revealing an AR-independent mechanism for this synergistic combination that is applicable to a variety of cancer types.

14 September 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
KKKonstantin Krismer
Konstantin Krismer
SVShohreh Varmeh
Shohreh Varmeh
MBMolly A. Bird
Molly A. Bird
AGAnna Gattinger
Anna Gattinger
YKYi Wen Kong
Yi Wen Kong
MYMichael B. Yaffe
Michael B. Yaffe
RNA-binding proteins (RBPs) play critical roles in regulating gene expression by modulating splicing, RNA stability, and protein translation. In response to various stimuli, alterations in RBP function contribute to global changes in gene expression, but identifying which specific RBPs are responsible for the observed changes in gene expression patterns remains an unmet need. Here, we present Transite a multi-pronged computational approach that systematically infers RBPs influencing gene expression changes through alterations in RNA stability and degradation. As a proof of principle, we applied Transite to public RNA expression data from human patients with non-small cell lung cancer whose tumors were sampled at diagnosis, or after recurrence following treatment with platinum-based chemotherapy. Transite implicated known RBP regulators of the DNA damage response and identified hnRNPC as a new modulator of chemotherapeutic resistance, which we subsequently validated experimentally. Transite serves as a generalizable framework for the identification of RBPs responsible for gene expression changes that drive cell-state transitions and adds additional value to the vast wealth of publicly-available gene expression data.